600216 浙江医药
已收盘 03-02 15:00:00
资讯
新帖
简况
每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金
证券之星 · 03-01 01:50
每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金
浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%
证券之星 · 02-24
浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%
浙江医药(600216.SH)拟参投合伙企业 投向银发经济/医药大健康领域
智通财经 · 02-24
浙江医药(600216.SH)拟参投合伙企业 投向银发经济/医药大健康领域
浙江医药：公司已经建立了财务共享体系
证券日报网 · 02-06
浙江医药：公司已经建立了财务共享体系
每周股票复盘：浙江医药（600216）国投高科减持期满未减持
证券之星 · 01-25
每周股票复盘：浙江医药（600216）国投高科减持期满未减持
浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，1月22日股价上涨1.7%
证券之星 · 01-22
浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，1月22日股价上涨1.7%
每周股票复盘：浙江医药（600216）完成1024.4万股限制性股票授予
证券之星 · 01-11
每周股票复盘：浙江医药（600216）完成1024.4万股限制性股票授予
浙江医药（600216）披露2025年限制性股票激励计划授予结果，1月6日股价上涨0.72%
证券之星 · 01-06
浙江医药（600216）披露2025年限制性股票激励计划授予结果，1月6日股价上涨0.72%
每周股票复盘：浙江医药（600216）完成限制性股票授予
证券之星 · 01-02
每周股票复盘：浙江医药（600216）完成限制性股票授予
浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%
证券之星 · 2025-11-26
浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%
浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市
智通财经 · 2025-11-26
浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市
每周股票复盘：浙江医药（600216）推1.07%股本激励计划
证券之星 · 2025-11-16
每周股票复盘：浙江医药（600216）推1.07%股本激励计划
浙江医药（600216）发布2025年限制性股票激励计划，11月13日股价上涨0.27%
证券之星 · 2025-11-13
浙江医药（600216）发布2025年限制性股票激励计划，11月13日股价上涨0.27%
每周股票复盘：浙江医药（600216）拟授1028.4万股限制性股票
证券之星 · 2025-11-09
每周股票复盘：浙江医药（600216）拟授1028.4万股限制性股票
浙江医药（600216）披露2025年限制性股票激励计划激励对象名单公示结果，11月07日股价上涨1.91%
证券之星 · 2025-11-07
浙江医药（600216）披露2025年限制性股票激励计划激励对象名单公示结果，11月07日股价上涨1.91%
浙江医药（600216）披露拟实施2025年限制性股票激励计划，11月05日股价下跌0.34%
证券之星 · 2025-11-05
浙江医药（600216）披露拟实施2025年限制性股票激励计划，11月05日股价下跌0.34%
每周股票复盘：浙江医药（600216）Q3净利降51.37%，推1028.4万股激励计划
证券之星 · 2025-11-02
每周股票复盘：浙江医药（600216）Q3净利降51.37%，推1028.4万股激励计划
浙江医药（600216）披露2025年限制性股票激励计划（草案），10月28日股价上涨0.49%
证券之星 · 2025-10-28
浙江医药（600216）披露2025年限制性股票激励计划（草案），10月28日股价上涨0.49%
图解浙江医药三季报：第三季度单季净利润同比下降51.37%
证券之星 · 2025-10-28
图解浙江医药三季报：第三季度单季净利润同比下降51.37%
浙江医药最新公告：拟投资16.85亿元建设昌北生物建设项目
证券之星 · 2025-10-27
浙江医药最新公告：拟投资16.85亿元建设昌北生物建设项目
加载更多
公司概况
公司名称：
浙江医药股份有限公司
所属行业：
医药制造业
上市日期：
1999-10-21
主营业务：
浙江医药股份有限公司的主营业务是生命营养品、药品。公司的主要产品是合成维生素E、维生素A、天然维生素E、维生素H(生物素)、维生素D3、辅酶Q10、β-胡萝卜素、斑蝥黄素、叶黄素、番茄红素等维生素和类维生素产品、医药制造类产品及医药商业。报告期内，公司在CPHI2025荣获“LeadingEnterpriseofPharmaInternationalizationAwards”（医药国际化领军企业奖），在HHB健康美丽产业高质量发展大会被评为“健康美丽产业绿色可持续发展先锋企业”。
发行价格：
5.16
{"stockData":{"symbol":"600216","market":"SH","secType":"STK","nameCN":"浙江医药","latestPrice":17.05,"timestamp":1772434800000,"preClose":16.29,"halted":0,"volume":57960592,"delay":0,"changeRate":0.0467,"floatShares":951000000,"shares":961999999,"eps":1.2937,"marketStatus":"已收盘","change":0.76,"latestTime":"03-02 15:00:00","open":16.1,"high":17.17,"low":16.03,"amount":978000000,"amplitude":0.07,"askPrice":17.06,"askSize":538,"bidPrice":17.05,"bidSize":366,"shortable":0,"etf":0,"ttmEps":1.2937,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772501400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.29,"symbolType":"stock","openAndCloseTimeList":[[1772415000000,1772422200000],[1772427600000,1772434800000]],"highLimit":17.92,"lowLimit":14.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":961637750,"isCdr":false,"pbRate":1.48,"roa":"--","peRate":13.179253,"roe":"8.49%","epsLYR":1.21,"committee":-0.803389,"marketValue":16396000000,"turnoverRate":0.0609,"status":0,"floatMarketCap":16221000000},"requestUrl":"/m/hq/s/600216","defaultTab":"news","newsList":[{"id":"2616843829","title":"每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843829","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843829?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:50","pubTimestamp":1772301020,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，浙江医药报收于16.29元，较上周的16.02元上涨1.69%。本周，浙江医药2月26日盘中最高价报16.71元。浙江医药当前最新总市值156.65亿元，在化学制药板块市值排名34/150，在两市A股市值排名1412/5189。本周关注点公司公告汇总：浙江医药拟出资2.5亿元参与设立银发经济股权投资基金。基金重点投向银发经济及医药大健康领域，存续期限为7年，管理人为中信医疗健康股权投资私募基金管理（北京）有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600216","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2613791683","title":"浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613791683?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:32","pubTimestamp":1771925558,"startTime":"0","endTime":"0","summary":"近日，浙江医药股份有限公司披露公告，公司与中信医疗健康股权投资私募基金管理（北京）有限公司等合作方共同投资设立廊坊信慧银发经济股权投资基金合伙企业，基金认缴出资总额为8亿元，公司作为有限合伙人以自有资金认缴出资2.5亿元，占比31.25%。基金重点投向银发经济及医药大健康领域，存续期限为7年，管理人为中信医疗健康股权投资私募基金管理（北京）有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","600216","BK0188","BK0028"],"gpt_icon":0},{"id":"2613927798","title":"浙江医药(600216.SH)拟参投合伙企业 投向银发经济/医药大健康领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2613927798","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613927798?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:50","pubTimestamp":1771919448,"startTime":"0","endTime":"0","summary":"合伙企业由中信医疗健康股权投资私募基金管理(北京)有限公司担任普通合伙人、执行事务合伙人和基金管理人。合伙企业重点投向银发经济/医药大健康领域的目标公司，促使被投资企业价值迅速提升，实现基金的设立目标，同时尽合理商业努力获得本基金资本的增值，并努力实现全体合伙人收益的最大化，从而实现多赢的结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK0188","09939","BK1161","600216","BK0239","BK0028","BK1515","BK0191","BK1574"],"gpt_icon":0},{"id":"2609962965","title":"浙江医药：公司已经建立了财务共享体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2609962965","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609962965?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:09","pubTimestamp":1770383340,"startTime":"0","endTime":"0","summary":"证券日报网讯 2月6日，浙江医药在互动平台回答投资者提问时表示，公司已经建立了财务共享体系，该体系正在根据业务实际需要完善调整中，公司根据业务流程特征与合规要求引入不同程度的自动化或智能化工具，公司财务共享体系根据业务需要分布在不同办公区域内。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-06/doc-inhkwwyc1990212.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-06/doc-inhkwwyc1990212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","600216","BK0239","BK0028","BK0191"],"gpt_icon":0},{"id":"2606358237","title":"每周股票复盘：浙江医药（600216）国投高科减持期满未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2606358237","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606358237?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:25","pubTimestamp":1769282712,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，浙江医药报收于14.73元，较上周的13.93元上涨5.74%。本周，浙江医药1月23日盘中最高价报14.99元。浙江医药当前最新总市值141.65亿元，在化学制药板块市值排名41/150，在两市A股市值排名1530/5182。公司公告汇总浙江医药股份有限公司持股5%以上股东国投高科技投资有限公司原计划通过集中竞价交易方式减持不超过9,616,377股，减持期间为2025年10月23日至2026年1月22日。本次减持计划未设置最低减持数量，实际减持情况与披露计划一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0191","BK0188","600216","BK0239"],"gpt_icon":0},{"id":"2605492266","title":"浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，1月22日股价上涨1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492266","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605492266?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:14","pubTimestamp":1769091259,"startTime":"0","endTime":"0","summary":"近日，浙江医药股份有限公司发布《持股5%以上股东减持计划届满暨未减持股份的公告》。公告显示，公司持股5%以上股东国投高科技投资有限公司原计划通过集中竞价交易方式减持不超过9,616,377股，减持期间为2025年10月23日至2026年1月22日。截至减持计划届满之日，国投高科未实施任何减持，仍持有公司股份150,127,573股，占总股本的15.61%。本次减持计划未设置最低减持数量，实际减持情况与披露计划一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","600216","BK0028","BK0188"],"gpt_icon":0},{"id":"2602398555","title":"每周股票复盘：浙江医药（600216）完成1024.4万股限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2602398555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602398555?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:30","pubTimestamp":1768077025,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，浙江医药报收于14.05元，较上周的13.86元上涨1.37%。本周，浙江医药1月7日盘中最高价报14.15元。浙江医药当前最新总市值135.11亿元，在化学制药板块市值排名44/150，在两市A股市值排名1542/5182。本周关注点公司公告汇总：浙江医药完成2025年限制性股票激励计划授予登记，实际授予1,024.4000万股，授予价格7.30元/股，涉及865人。股票来源于二级市场回购，总股本不变。限售期分别为12个月和24个月，分两期各解除限售50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0191","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2601526815","title":"浙江医药（600216）披露2025年限制性股票激励计划授予结果，1月6日股价上涨0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601526815","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601526815?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:45","pubTimestamp":1767710718,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，浙江医药报收于14.06元，较前一交易日上涨0.72%，最新总市值为135.21亿元。公司近日发布公告，披露2025年限制性股票激励计划的授予结果。公告显示，本次限制性股票激励计划的授予日为2025年11月26日，登记日为2026年1月5日，实际授予股份数量为1,024.4000万股，授予价格为7.30元/股，共有865名激励对象获授，包括公司董事、高级管理人员及核心骨干员工。限售期分别为12个月和24个月，解除限售比例分两期各为50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0191","BK0188","600216","BK0239"],"gpt_icon":0},{"id":"2600036136","title":"每周股票复盘：浙江医药（600216）完成限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036136","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036136?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:04","pubTimestamp":1767294252,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，浙江医药报收于13.83元，较上周的13.95元下跌0.86%。本周，浙江医药12月22日盘中最高价报14.01元。浙江医药当前最新总市值133.28亿元，在化学制药板块市值排名39/150，在两市A股市值排名1459/5181。本周关注点公司公告汇总：浙江医药向865名激励对象授予1,024.4000万股限制性股票，行权款总额7,478.12万元。本次授予股票来源于公司从二级市场回购的A股普通股，股份性质将由无限售条件流通股变更为有限售条件流通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600216","BK0188","BK0191"],"gpt_icon":0},{"id":"2586268215","title":"浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586268215","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586268215?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:22","pubTimestamp":1764166946,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘，浙江医药报收于14.03元，较前一交易日上涨0.14%，最新总市值为134.92亿元。该股当日开盘14.0元，最高14.22元，最低13.99元，成交额达1.02亿元，换手率为0.75%。近日，浙江医药发布公告称，公司已于2025年11月26日向875名激励对象授予1,028.4000万股限制性股票，授予价格为7.30元/股。授予条件已满足，限售期分别为12个月和24个月，分两期各解除限售50%。本次股权激励费用将在2025年至2027年摊销，预计总费用为6,921.13万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600038961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0191","600216","BK0028"],"gpt_icon":0},{"id":"2586625833","title":"浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586625833","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586625833?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:51","pubTimestamp":1764150660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浙江医药(600216.SH)发布公告，为更好地促进公司药品生物制剂板块的发展，充分发挥资本市场优化资源配置的作用，拓宽融资渠道，从而提升公司整体的盈利能力和核心竞争力，公司拟筹划分拆控股子公司浙江新码生物医药有限公司(简称“新码生物”)于香港联合交易所有限公司(简称“香港联交所”)上市。本次分拆上市事项如若实施，不会导致公司丧失对新码生物的控制权，不会对公司其他业务板块的经营发展和公司整体的持续盈利能力造成重大不利影响，不会损害公司的独立上市地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0191","600216","BK0028","BK0239"],"gpt_icon":0},{"id":"2583659570","title":"每周股票复盘：浙江医药（600216）推1.07%股本激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659570","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659570?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:06","pubTimestamp":1763229977,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，浙江医药报收于14.86元，较上周的14.91元下跌0.34%。本周，浙江医药11月12日盘中最高价报15.12元。本周关注点公司公告汇总：浙江医药拟向875名激励对象授予不超过1,028.4000万股限制性股票，占公司股本总额的1.0694%。公司公告汇总：2025年第一次临时股东会审议通过限制性股票激励计划相关议案。公司对2025年限制性股票激励计划内幕信息知情人在2025年4月28日至10月27日期间的股票买卖情况进行了自查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0191","BK0028","600216"],"gpt_icon":0},{"id":"2583599881","title":"浙江医药（600216）发布2025年限制性股票激励计划，11月13日股价上涨0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583599881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583599881?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:26","pubTimestamp":1763043983,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，浙江医药报收于15.01元，较前一交易日上涨0.27%，最新总市值为144.34亿元。该股当日开盘15.03元，最高15.04元，最低14.9元，成交额达1.61亿元，换手率为1.12%。近日，浙江医药发布2025年限制性股票激励计划，拟向875名激励对象授予不超过1,028.4000万股限制性股票，占公司股本总额的1.0694%。本计划有效期不超过36个月，解除限售期分为两个阶段，分别在授予登记完成后的12个月和24个月后解除限售，解除限售比例均为50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600216","BK0191","BK0028"],"gpt_icon":0},{"id":"2582265869","title":"每周股票复盘：浙江医药（600216）拟授1028.4万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2582265869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582265869?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:04","pubTimestamp":1762628655,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，浙江医药报收于14.91元，较上周的14.56元上涨2.4%。本周关注点公司公告汇总：浙江医药拟授予不超过1,028.4000万股限制性股票，占总股本1.0694%。公司公告汇总浙江医药股份有限公司拟实施2025年限制性股票激励计划，旨在健全长效激励机制，吸引和留住优秀人才，调动董事、高管及核心骨干积极性。浙江医药于2025年10月27日召开董事会审议通过2025年限制性股票激励计划（草案）及相关议案，并于10月28日在上交所网站披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0188","BK0239","BK0028","BK0191"],"gpt_icon":0},{"id":"2581929889","title":"浙江医药（600216）披露2025年限制性股票激励计划激励对象名单公示结果，11月07日股价上涨1.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581929889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581929889?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:24","pubTimestamp":1762525465,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，董事会薪酬与考核委员会对2025年限制性股票激励计划激励对象名单的公示情况进行了核查。浙江医药于2025年10月27日召开董事会，审议通过2025年限制性股票激励计划（草案）及相关议案，并于10月28日在上交所网站披露。公司随后在内部网站公示了本次激励计划的激励对象名单，公示期为2025年10月28日至11月6日，在此期间未收到任何异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700039209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0191","600216","BK0028"],"gpt_icon":0},{"id":"2581077514","title":"浙江医药（600216）披露拟实施2025年限制性股票激励计划，11月05日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581077514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581077514?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:19","pubTimestamp":1762352362,"startTime":"0","endTime":"0","summary":"根据近日发布的公告，浙江医药股份有限公司拟实施2025年限制性股票激励计划，旨在健全长效激励机制，吸引和留住优秀人才，调动董事、高管及核心骨干积极性。相关议案包括《2025年限制性股票激励计划（草案）》及其摘要、《实施考核管理办法》及提请股东大会授权董事会办理激励计划相关事项。上述议案已于2025年10月27日经第十届董事会第八次会议审议通过，并于2025年11月13日提交临时股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600216","BK0239","BK0028","BK0191"],"gpt_icon":0},{"id":"2580547671","title":"每周股票复盘：浙江医药（600216）Q3净利降51.37%，推1028.4万股激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2580547671","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580547671?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:05","pubTimestamp":1762027517,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，浙江医药报收于14.56元，较上周的14.44元上涨0.83%。本周，浙江医药10月29日盘中最高价报14.89元。公司公告汇总：拟实施2025年限制性股票激励计划，授予1028.4万股，占总股本1.0694%。股本股东变化截至2025年9月30日，浙江医药股东户数为6.3万户，较6月30日减少2510户，减幅3.83%。业绩披露要点浙江医药2025年三季报显示，主营收入66.95亿元，同比下降5.87%；归母净利润9.33亿元，同比上升9.83%；扣非净利润8.91亿元，同比上升5.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0191","600216","BK0239"],"gpt_icon":0},{"id":"2578934220","title":"浙江医药（600216）披露2025年限制性股票激励计划（草案），10月28日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578934220","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578934220?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:11","pubTimestamp":1761646277,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，浙江医药报收于14.5元，较前一交易日上涨0.49%，最新总市值为139.44亿元。该股当日开盘14.4元，最高14.59元，最低14.36元，成交额达2.09亿元，换手率为1.5%。同日，浙江医药发布《2025年限制性股票激励计划（草案）》，拟向875名激励对象授予不超过1,028.4000万股限制性股票，占公司股本总额的1.0694%，股票来源为二级市场回购。本计划有效期不超过36个月，限售期为12个月、24个月，分两期各解除限售50%。本计划经股东大会审议通过后实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800034207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","600216","BK0028","BK0188"],"gpt_icon":0},{"id":"2578622529","title":"图解浙江医药三季报：第三季度单季净利润同比下降51.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622529","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578622529?lang=zh_cn&edition=full","pubTime":"2025-10-28 02:23","pubTimestamp":1761589389,"startTime":"0","endTime":"0","summary":"证券之星消息，浙江医药2025年三季报显示，公司主营收入66.95亿元，同比下降5.87%；归母净利润9.33亿元，同比上升9.83%；扣非净利润8.91亿元，同比上升5.3%；其中2025年第三季度，公司单季度主营收入23.72亿元，同比下降12.37%；单季度归母净利润2.6亿元，同比下降51.37%；单季度扣非净利润2.25亿元，同比下降57.41%；负债率20.69%，投资收益536.49万元，财务费用-9326.39万元，毛利率37.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800001999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216"],"gpt_icon":0},{"id":"2578683648","title":"浙江医药最新公告：拟投资16.85亿元建设昌北生物建设项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2578683648","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578683648?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:18","pubTimestamp":1761563927,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，公司子公司昌北生物拟投资16.85亿元建设浙江医药昌北生物建设项目，项目分两期建设，旨在提升维生素等产品原辅料的自给能力，降低关键中间体对外的依存度。项目建成后，预计年销售额可达9亿元，毛利2.86亿元。本项目投资是基于公司发展战略和业务布局而作出的审慎决策，但未来经营效益的实现存在一定不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700029961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600216","BK0191","BK0028","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772439018355,"stockEarnings":[{"period":"1week","weight":0.0169},{"period":"1month","weight":0.1344},{"period":"3month","weight":0.1611},{"period":"6month","weight":0.0402},{"period":"1year","weight":0.0416},{"period":"ytd","weight":0.1753}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63021人(较上一季度减少3.83%)","perCapita":"15096股","listingDate":"1999-10-21","address":"浙江省绍兴市越城区滨海新城致远中大道168号","registeredCapital":"96163万元","survey":" 浙江医药股份有限公司的主营业务是生命营养品、药品。公司的主要产品是合成维生素E、维生素A、天然维生素E、维生素H(生物素)、维生素D3、辅酶Q10、β-胡萝卜素、斑蝥黄素、叶黄素、番茄红素等维生素和类维生素产品、医药制造类产品及医药商业。报告期内，公司在CPHI2025荣获“LeadingEnterpriseofPharmaInternationalizationAwards”（医药国际化领军企业奖），在HHB健康美丽产业高质量发展大会被评为“健康美丽产业绿色可持续发展先锋企业”。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浙江医药,600216,浙江医药股票,浙江医药股票老虎,浙江医药股票老虎国际,浙江医药行情,浙江医药股票行情,浙江医药股价,浙江医药股市,浙江医药股票价格,浙江医药股票交易,浙江医药股票购买,浙江医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}